00:51 , May 31, 2019 |  BC Innovations  |  Targets & Mechanisms

Targeting cancer evolution offers a way to foil drug resistance

A growing crop of researchers and companies are tackling cancer drug resistance by preempting tumors’ tendencies to adapt, rather than responding to resistance after it develops. Though still in their infancy, these therapies could get...
19:35 , Jan 18, 2019 |  BioCentury  |  Emerging Company Profile

Achilles’ truncal neoantigens

Achilles Therapeutics Ltd. is developing a personalized T cell therapy that uses “truncal” neoantigens expressed in all tumor cells to drive T cells selected from tumor-infiltrating lymphocytes (TILs). Neoantigen discovery is fueling a burst of...
19:20 , Nov 17, 2017 |  BC Week In Review  |  Company News

Sixth Element, PhoreMost spin out immuno-oncology newco

Sixth Element Capital LLC invested £3 million ($4 million) in newly created NeoPhore Ltd. (Cambridge, U.K.), a spinout from cancer company PhoreMost Ltd. (Cambridge, U.K.). The newco will seek to discover and develop small molecule...
15:11 , Sep 1, 2017 |  BC Week In Review  |  Financial News

Macrophage raises L3M to close L12M series A

On Aug. 23, immuno-oncology company Macrophage Pharma Ltd. (Windsor, U.K.) said it raised £3 million ($3.9 million) from new investor Merck Ventures in the final tranche of a £12 million ($15.4 million) series A round....
22:38 , Jul 20, 2017 |  BC Innovations  |  Finance

Sharpless edge for NCI

The National Cancer Institute is poised to enter a new phase, under the leadership of Norman (Ned) Sharpless, following the June 9 announcement by the White House of the president’s choice to fill the large...
20:15 , May 25, 2017 |  BC Innovations  |  Finance

Europe’s translational springtime

European science is showing early signs of translational growth, with VCs increasingly shifting their focus to preclinical assets. But investors are concerned the region still doesn’t have the supply of management talent or funding it...
23:13 , Apr 18, 2017 |  BC Extra  |  Financial News

Cancer Research UK, NCI funding Ras research

Cancer Research UK and the Cancer Research Technology Pioneer Fund will commit £2.5 million ($3.1 million) to collaborate with the National Cancer Institute on research of inhibitors of Ras , long considered an important yet...
22:27 , Mar 16, 2017 |  BC Innovations  |  Product R&D

Neo wave

The central thesis in the increasingly hot field of neoantigens is to pick mutations from patient tumors and turn them into personalized immunotherapies. While companies are staking out their space by defining how they will...
16:23 , Jan 12, 2017 |  BC Week In Review  |  Financial News

Macrophage completes venture financing

Macrophage raised £9 million ($11 million) in a series A round led by CRT Pioneer Fund. Novo Seeds and Aglaia Biomedical Ventures also participated. Macrophage Pharma Ltd. , Windsor, U.K. ...
19:41 , Nov 11, 2016 |  BC Week In Review  |  Company News

Wellcome Trust, BACIT, Cancer Research UK deal

Wellcome Trust , London, U.K.  BACIT Ltd. (LSE:BACT), London, U.K.  Cancer Research UK , London, U.K.  Business: Cancer  The Syncona investment arm of the Wellcome Trust and cancer-focused investment firm BACIT proposed a deal in...